Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2017; 37(02): 167-175
DOI: 10.1055/s-0037-1601894
DOI: 10.1055/s-0037-1601894
Review Article
Characterizing Cognitive Impairment in Parkinson's Disease
Further Information
Publication History
Publication Date:
16 May 2017 (online)
Abstract
Cognitive impairment is a frequent complication in Parkinson's disease (PD), though it can be heterogeneous in its presentation and progression. Cognitive deficits vary among patients with regard to clinical features, severity, and progression to dementia. A growing recognition of cognitive impairment in PD in both the clinical and research settings has led to advances in diagnostic criteria and improved understanding of the clinical phenotypes, associated biomarkers, and underlying pathophysiology of both PD dementia and PD mild cognitive impairment. Therapeutic interventions are geared to improve symptoms and ideally to prevent cognitive decline. Here the authors summarize the current research on the characterization of cognitive impairment in PD, with specific attention focused on its clinical phenotype, associated neuropsychiatric and prodromal features, pathological changes, genetic variations, and imaging and biochemical biomarkers.
-
References
- 1 Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23 (6) 837-844
- 2 Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010; 289 (1-2): 18-22
- 3 Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 2012; 25 (4) 208-214
- 4 Emre M, Aarsland D, Brown R , et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22 (12) 1689-1707 , quiz 1837
- 5 Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord 2014; 29 (5) 608-621
- 6 Aarsland D, Bronnick K, Williams-Gray C , et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75 (12) 1062-1069
- 7 Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord 2012; 27 (9) 1129-1136
- 8 Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G ; Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72 (13) 1121-1126
- 9 Litvan I, Goldman JG, Tröster AI , et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27 (3) 349-356
- 10 Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013; 70 (5) 580-586
- 11 Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013; 81 (4) 346-352
- 12 Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127 (Pt 3): 550-560
- 13 Yarnall AJ, Breen DP, Duncan GW , et al; ICICLE-PD Study Group. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014; 82 (4) 308-316
- 14 Chahine LM, Weintraub D, Hawkins KA , et al; PARS Investigators. Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Mov Disord 2016; 31 (1) 86-94
- 15 Williams-Gray CH, Evans JR, Goris A , et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132 (Pt 11): 2958-2969
- 16 Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A. Parkinson's Disease-Cognitive Rating Scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008; 23 (7) 998-1005
- 17 Marras C, Tröster AI, Kulisevsky J, Stebbins GT. The tools of the trade: a state of the art “how to assess cognition” in the patient with Parkinson's disease. Mov Disord 2014; 29 (5) 584-596
- 18 Aarsland D, Taylor JP, Weintraub D. Psychiatric issues in cognitive impairment. Mov Disord 2014; 29 (5) 651-662
- 19 Lawson RA, Yarnall AJ, Duncan GW , et al; ICICLE-PD study group. Cognitive decline and quality of life in incident Parkinson's disease: the role of attention. Parkinsonism Relat Disord 2016; 27: 47-53
- 20 Forsaa EB, Larsen JP, Wentzel-Larsen T , et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67 (8) 996-1001
- 21 Fénelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289 (1-2): 12-17
- 22 Muller AJ, Shine JM, Halliday GM, Lewis SJ. Visual hallucinations in Parkinson's disease: theoretical models. Mov Disord 2014; 29 (13) 1591-1598
- 23 Tremblay C, Achim AM, Macoir J, Monetta L. The heterogeneity of cognitive symptoms in Parkinson's disease: a meta-analysis. J Neurol Neurosurg Psychiatry 2013; 84 (11) 1265-1272
- 24 Monastero R, Di Fiore P, Ventimiglia GD, Camarda R, Camarda C. The neuropsychiatric profile of Parkinson's disease subjects with and without mild cognitive impairment. J Neural Transm (Vienna) 2013; 120 (4) 607-611
- 25 Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015; 14 (5) 518-531
- 26 Riedel O, Klotsche J, Spottke A , et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol 2010; 257 (7) 1073-1082
- 27 Hu Y, Yu SY, Zuo LJ , et al. Parkinson disease with REM sleep behavior disorder: features, α-synuclein, and inflammation. Neurology 2015; 84 (9) 888-894
- 28 Gagnon JF, Vendette M, Postuma RB , et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol 2009; 66 (1) 39-47
- 29 Postuma RB, Bertrand JA, Montplaisir J , et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study. Mov Disord 2012; 27 (6) 720-726
- 30 Goldman JG, Ghode RA, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord 2013; 19 (9) 806-811
- 31 Bolitho SJ, Naismith SL, Salahuddin P, Terpening Z, Grunstein RR, Lewis SJ. Objective measurement of daytime napping, cognitive dysfunction and subjective sleepiness in Parkinson's disease. PLoS One 2013; 8 (11) e81233
- 32 Gunn DG, Naismith SL, Terpening Z, Lewis SJ. The relationships between poor sleep efficiency and mild cognitive impairment in Parkinson disease. J Geriatr Psychiatry Neurol 2014; 27 (2) 77-84
- 33 Latreille V, Carrier J, Lafortune M , et al. Sleep spindles in Parkinson's disease may predict the development of dementia. Neurobiol Aging 2015; 36 (2) 1083-1090
- 34 Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 2014; 29 (5) 634-650
- 35 Compta Y, Parkkinen L, O'Sullivan SS , et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011; 134 (Pt 5): 1493-1505
- 36 Irwin DJ, White MT, Toledo JB , et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72 (4) 587-598
- 37 Adler CH, Caviness JN, Sabbagh MN , et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010; 120 (6) 827-828
- 38 Jellinger KA. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010; 120 (6) 829-830 , author reply 831
- 39 Robbins TW, Cools R. Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective. Mov Disord 2014; 29 (5) 597-607
- 40 Vaillancourt DE, Schonfeld D, Kwak Y, Bohnen NI, Seidler R. Dopamine overdose hypothesis: evidence and clinical implications. Mov Disord 2013; 28 (14) 1920-1929
- 41 Foltynie T, Lewis SG, Goldberg TE , et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol 2005; 252 (7) 833-838
- 42 Białecka M, Kurzawski M, Roszmann A , et al. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease. Neurosci Lett 2014; 561: 86-90
- 43 Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221 (2) 564-573
- 44 Perry EK, Curtis M, Dick DJ , et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48 (5) 413-421
- 45 Mattila PM, Röyttä M, Lönnberg P, Marjamäki P, Helenius H, Rinne JO. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol 2001; 102 (2) 160-166
- 46 Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; (3) CD006504
- 47 Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry 2013; 84 (7) 774-783
- 48 Isaias IU, Marotta G, Pezzoli G , et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurol 2011; 11: 88
- 49 Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. Neuroimage 2011; 56 (3) 1463-1468
- 50 Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009; 24 (2) 277-282
- 51 Huot P, Johnston TH, Darr T , et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010; 25 (10) 1399-1408
- 52 Wicke K, Haupt A, Bespalov A. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease. Expert Opin Investig Drugs 2015; 24 (12) 1515-1528
- 53 Kasten M, Klein C. The many faces of alpha-synuclein mutations. Mov Disord 2013; 28 (6) 697-701
- 54 Guella I, Evans DM, Szu-Tu C , et al; SNCA Cognition Study Group. α-synuclein genetic variability: a biomarker for dementia in Parkinson disease. Ann Neurol 2016; 79 (6) 991-999
- 55 Alcalay RN, Caccappolo E, Mejia-Santana H , et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012; 78 (18) 1434-1440
- 56 Setó-Salvia N, Clarimón J, Pagonabarraga J , et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011; 68 (3) 359-364
- 57 Winder-Rhodes SE, Evans JR, Ban M , et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013; 136 (Pt 2): 392-399
- 58 Davis MY, Johnson CO, Leverenz JB , et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurol 2016; 73 (10) 1217-1224
- 59 Beavan MS, Schapira AH. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 2013; 45 (8) 511-521
- 60 Mata IF, Leverenz JB, Weintraub D , et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 2014; 71 (11) 1405-1412
- 61 Morley JF, Xie SX, Hurtig HI , et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012; 27 (4) 512-518
- 62 Tsuang D, Leverenz JB, Lopez OL , et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013; 70 (2) 223-228
- 63 Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jiménez-Urbieta H, Rodriguez-Oroz MC. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease. Mov Disord 2016; 31 (6) 861-881
- 64 Thaler A, Mirelman A, Gurevich T , et al; LRRK2 Ashkenazi Jewish Consortium. Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology 2012; 79 (10) 1027-1032
- 65 Caccappolo E, Alcalay RN, Mejia-Santana H , et al. Neuropsychological profile of parkin mutation carriers with and without Parkinson disease: the CORE-PD Study. J Int Neuropsychol Soc 2011; 17 (1) 91-100
- 66 Montine TJ, Shi M, Quinn JF , et al. CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010; 25 (15) 2682-2685
- 67 Compta Y, Valente T, Saura J , et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease. J Neurol 2015; 262 (2) 294-306
- 68 Compta Y, Pereira JB, Ríos J , et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013; 19 (8) 717-724
- 69 Vranová HP, Hényková E, Kaiserová M , et al. Tau protein, beta-amyloid1−42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci 2014; 343 (1-2): 120-124
- 70 Yu SY, Zuo LJ, Wang F , et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol 2014; 14: 113
- 71 Hall S, Öhrfelt A, Constantinescu R , et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012; 69 (11) 1445-1452
- 72 Wennström M, Surova Y, Hall S , et al. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 2013; 8 (1) e53250
- 73 Hansson O, Hall S, Ohrfelt A , et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther 2014; 6 (3) 25
- 74 Stewart T, Liu C, Ginghina C , et al; Parkinson Study Group DATATOP Investigators. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014; 184 (4) 966-975
- 75 Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (7) 758-764
- 76 Lindqvist D, Hall S, Surova Y , et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013; 33: 183-189
- 77 Peterson AL, Murchison C, Zabetian C , et al. Memory, mood, and vitamin D in persons with Parkinson's disease. J Parkinsons Dis 2013; 3 (4) 547-555
- 78 Li Z, Zhang J, Sun H. Increased plasma levels of phospholipid in Parkinson's disease with mild cognitive impairment. J Clin Neurosci 2015; 22 (8) 1268-1271
- 79 Connolly J, Siderowf A, Clark CM, Mu D, Pratico D. F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn Behav Neurol 2008; 21 (2) 83-86
- 80 Mielke MM, Maetzler W, Haughey NJ , et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS One 2013; 8 (9) e73094
- 81 Lim NS, Swanson CR, Cherng HR , et al; PARS Investigators; Alzheimer's Disease Neuroimaging Initiative. Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. Ann Clin Transl Neurol 2016; 3 (5) 346-355
- 82 Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011; 26 (2) 289-296
- 83 Choi SH, Jung TM, Lee JE, Lee SK, Sohn YH, Lee PH. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol Aging 2012; 33 (7) 1265-1272
- 84 Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y , et al. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. PLoS One 2013; 8 (1) e54980
- 85 Lee JE, Cho KH, Song SK , et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2014; 85 (1) 7-16
- 86 Kandiah N, Zainal NH, Narasimhalu K , et al. Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. Parkinsonism Relat Disord 2014; 20 (11) 1203-1208
- 87 Agosta F, Canu E, Stefanova E , et al. Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage. Hum Brain Mapp 2014; 35 (5) 1921-1929
- 88 Melzer TR, Watts R, MacAskill MR , et al. White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology 2013; 80 (20) 1841-1849
- 89 Hattori T, Orimo S, Aoki S , et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 2012; 33 (3) 727-739
- 90 Ekman U, Eriksson J, Forsgren L , et al. Longitudinal changes in task-evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment. Front Neurosci 2014; 8: 207
- 91 Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012; 11 (8) 679-687
- 92 Nombela C, Rowe JB, Winder-Rhodes SE , et al; ICICLE-PD study group. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2014; 137 (Pt 10): 2743-2758
- 93 Winder-Rhodes SE, Hampshire A, Rowe JB , et al. Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. Neurobiol Aging 2015; 36 (3) 1519-1528
- 94 Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008; 22 (1) 54-60
- 95 Nie K, Zhang Y, Huang B , et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism Relat Disord 2013; 19 (3) 329-334
- 96 Pagonabarraga J, Gómez-Ansón B, Rotger R , et al. Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease. Dement Geriatr Cogn Disord 2012; 34 (5-6): 312-318
- 97 Shimada H, Hirano S, Shinotoh H , et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73 (4) 273-278
- 98 Bohnen NI, Müller ML, Kotagal V , et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012; 32 (8) 1609-1617
- 99 Lorenz R, Samnick S, Dillmann U , et al. Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease. Acta Neurol Scand 2014; 130 (3) 164-171
- 100 Garcia-Garcia D, Clavero P, Gasca Salas C , et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging 2012; 39 (11) 1767-1777
- 101 Kramberger MG, Stukovnik V, Cus A , et al. Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment. Psychiatr Danub 2010; 22 (3) 446-449
- 102 Campbell MC, Markham J, Flores H , et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013; 81 (6) 520-527
- 103 Gomperts SN, Locascio JJ, Marquie M , et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27 (8) 965-973
- 104 Gomperts SN, Locascio JJ, Rentz D , et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80 (1) 85-91